Seek Returns

ILMN vs. KYMR: Illumina vs. Kymera Therapeutics Stock Comparison

How do Illumina (ILMN) and Kymera Therapeutics (KYMR) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Illumina (ILMN) and Kymera Therapeutics (KYMR) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ILMN is classified in Life Sciences Tools & Services while KYMR is classified in Biotechnology.

Illumina (ILMN) has more than two decades of public-market history since July 28, 2000, whereas Kymera Therapeutics (KYMR) listed on August 21, 2020 and has a much shorter record to draw on.

Company profile comparison for Illumina (ILMN) and Kymera Therapeutics (KYMR)
Profile ItemILMNKYMR
NameIllumina Inc.Kymera Therapeutics Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesBiotechnology
GICS Sub-IndustryLife Sciences Tools & ServicesBiotechnology
Market Capitalization32.23 billion USD11.25 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateJuly 28, 2000August 21, 2020
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

ILMN
KYMR
GSPC
Loading price history…
Illumina (ILMN) vs. Kymera Therapeutics (KYMR), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Illumina (ILMN) and Kymera Therapeutics (KYMR). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Illumina (ILMN) and Kymera Therapeutics (KYMR). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Illumina (ILMN) and Kymera Therapeutics (KYMR)
MetricILMNKYMR
Total Return (1Y)79.70%131.52%
Total Return (3Y, Annualized)28.16%111.65%
Total Return (5Y, Annualized)-10.65%15.68%

Risk Profile

Drawdown History

ILMN
KYMR
GSPC
Loading price history…
Illumina (ILMN) vs. Kymera Therapeutics (KYMR), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Illumina (ILMN) and Kymera Therapeutics (KYMR). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Illumina (ILMN) and Kymera Therapeutics (KYMR)
MetricILMNKYMR
Volatility (1Y, Annualized)48.47%62.83%
Beta (5Y)1.462.00
Max Drawdown (5Y)-82.95%-83.27%
Avg. Volume (3M)2.77M833.05K

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
ILMN and KYMR are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Illumina (ILMN) and Kymera Therapeutics (KYMR)
MetricILMNKYMR
Sharpe Ratio (1Y)1.562.03
Sortino Ratio (1Y)2.254.16

Profitability

ROE (TTM)

Kymera Therapeutics (KYMR) reports a negative ROE of -27.29%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Illumina (ILMN) reports 32.39%, ranking against industry peers normally.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

32.39%

Max
109.18%
ILMN
32.39%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

-27.29%

Max
109.18%
Q3
6.23%
Median
-26.66%
KYMR
-27.29%
Q1
-64.05%
Min
-167.77%
Loading chart…
Illumina (ILMN) vs. Kymera Therapeutics (KYMR): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Illumina (ILMN) at 19.72% converts revenue to bottom-line profit above its industry’s benchmark range, while Kymera Therapeutics (KYMR) at 0.00% keeps roughly the typical share for its industry.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.72%

ILMN
19.72%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
18.05%
Q3
4.78%
KYMR
0.00%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Illumina (ILMN) vs. Kymera Therapeutics (KYMR): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Kymera Therapeutics (KYMR) reports a negative operating margin of -396.04%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Illumina (ILMN) reports 20.02%, ranking against industry peers normally.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.02%

Max
83.12%
ILMN
20.02%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

-396.04%

Max
83.12%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
KYMR
-396.04%
Loading chart…
Illumina (ILMN) vs. Kymera Therapeutics (KYMR): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Illumina (ILMN) and Kymera Therapeutics (KYMR)
MetricILMNKYMR
ROE (TTM)32.39%-27.29%
ROA (TTM)8.32%-17.64%
Net Margin (TTM)19.72%0.00%
Operating Margin (TTM)20.02%-396.04%
Gross Margin (TTM)67.68%0.00%

Growth

Revenue Growth

Both Illumina (ILMN) at -0.66% and Kymera Therapeutics (KYMR) at -16.70% post bottom-quartile revenue growth versus peers, pointing to weaker demand or pricing momentum than typical rivals.

Loading chart…
Illumina (ILMN) vs. Kymera Therapeutics (KYMR): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither Illumina (ILMN) nor Kymera Therapeutics (KYMR) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Growth metrics for Illumina (ILMN) and Kymera Therapeutics (KYMR)
MetricILMNKYMR
Revenue Growth (YoY)-0.66%-16.70%
Revenue Growth (3Y CAGR)-1.78%-5.74%
EPS Growth (YoY)----
EPS Growth (3Y CAGR)----

Financial Strength

Current Ratio (MRQ)

Both Illumina (ILMN) at 2.63 and Kymera Therapeutics (KYMR) at 11.13 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.63

Max
25.13
Q3
12.13
Median
5.52
ILMN
2.63
Q1
2.47
Min
0.10

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

11.13

Max
25.13
Q3
12.13
KYMR
11.13
Median
5.52
Q1
2.47
Min
0.10
Loading chart…
Illumina (ILMN) vs. Kymera Therapeutics (KYMR): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Kymera Therapeutics (KYMR) at 0.05 carries an industry-typical debt-to-equity mix, while Illumina (ILMN) at 0.74 uses more debt funding than most peers.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.74

Max
1.42
ILMN
0.74
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.05

Max
1.42
Q3
0.65
Median
0.15
KYMR
0.05
Q1
0.02
Min
0.00
Loading chart…
Illumina (ILMN) vs. Kymera Therapeutics (KYMR): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Illumina (ILMN) and Kymera Therapeutics (KYMR)
MetricILMNKYMR
Current Ratio (MRQ)2.6311.13
Debt / Equity (MRQ)0.740.05
Net Debt / EBITDA0.85--

Dividends

Dividend Yield (TTM)

Neither Illumina (ILMN) nor Kymera Therapeutics (KYMR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ILMN
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

KYMR
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Illumina (ILMN) vs. Kymera Therapeutics (KYMR): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Illumina (ILMN) nor Kymera Therapeutics (KYMR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ILMN
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

KYMR
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Illumina (ILMN) vs. Kymera Therapeutics (KYMR): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Illumina (ILMN) and Kymera Therapeutics (KYMR)
MetricILMNKYMR
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Illumina (ILMN) trades at 36.68 times trailing earnings, ranked against its peers, while Kymera Therapeutics (KYMR) has no P/E ratio this period.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

36.68

Max
85.34
Q3
43.46
ILMN
36.68
Median
26.69
Q1
13.30
Min
0.07

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
KYMR
--
Loading chart…
Illumina (ILMN) vs. Kymera Therapeutics (KYMR): KYMR does not report P/E ratio, so it has no value marker; ILMN is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

Illumina (ILMN) at 7.10 prices around its industry’s typical P/S ratio, while Kymera Therapeutics (KYMR) at 110.00 clears its benchmark range — KYMR looks notably rich on sales.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.10

Max
58.18
Q3
25.77
Median
7.30
ILMN
7.10
Q1
3.01
Min
0.01

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

110.00

KYMR
110.00
Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
Min
0.01
Loading chart…
Illumina (ILMN) vs. Kymera Therapeutics (KYMR): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both Illumina (ILMN) at 10.30 and Kymera Therapeutics (KYMR) at 6.96 carry a premium to book value versus peers, sitting in the upper P/B ratio quartile of their industries.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.30

Max
13.53
ILMN
10.30
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.96

Max
13.53
KYMR
6.96
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Illumina (ILMN) vs. Kymera Therapeutics (KYMR): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Illumina (ILMN) and Kymera Therapeutics (KYMR)
MetricILMNKYMR
P/E Ratio (TTM)36.68--
P/S Ratio (TTM)7.10110.00
P/B Ratio (MRQ)10.306.96
Free Cash Flow Yield (TTM)2.67%-1.46%